about
Therapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisModulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsBeyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen's chaperone activityHuman apolipoprotein A-I-derived amyloid: its association with atherosclerosisHuman apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensityAmyloidogenic propensity of a natural variant of human apolipoprotein A-I: stability and interaction with ligandsAmyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.Delineation of concentration ranges and longitudinal changes of human plasma protein variants.Mysterious oligomerization of the amyloidogenic proteinsThe relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry.Prediction of regulatory networks in mouse abdominal wallOutcome of gastric emptying and gastrointestinal symptoms after liver transplantation for hereditary transthyretin amyloidosis.Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis.Acute phase reactants as novel predictors of cardiovascular disease.Abeta aggregation and possible implications in Alzheimer's disease pathogenesisEffects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosisEffects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitroTHAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy.A Novel Plasma Based Biomarker of Alzheimer's Disease.Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregationSynthesis and structural analysis of the N-terminal domain of the thyroid hormone-binding protein transthyretin.Three-dimensional structure of the transthyretin-retinol-binding protein complex.Under-folded proteins: Conformational ensembles and their roles in protein folding, function, and pathogenesis.Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point.
P2860
Q26782089-0A9F15F2-A544-4628-A744-90A07A3E17AFQ28259424-CB668366-1A44-45EB-A8DC-11360114C0CAQ28477682-938CAEF2-BC6D-4919-88D1-4938DCB843CCQ28479210-4DB2FF4E-F130-49CE-936C-470687ACF970Q28482893-81AAC834-C7B5-44BC-B868-98587CB715ADQ28547085-5637CD4D-AD4D-40F7-B379-9D937026D011Q33334024-C4CD2FAE-8867-405E-88C1-15EB924E0F7EQ33793513-94CCCE97-1769-4BF8-A85E-337736054361Q34046583-936DF3EC-84A8-412D-A853-9C0E3654E743Q34073701-03630638-6E40-466A-B7AA-D493A04A17AEQ34209394-DC033D6D-6674-4922-98F3-C61A54187DD8Q35556198-14737329-B0FF-4CA0-8B93-44005301F36EQ36142761-96241B6E-B46E-428C-8627-4B920C958577Q36927938-3F79A471-7B4A-4A5F-9E23-31A25CC39322Q37156874-050002E6-C00B-45CF-A6A9-63DEBC0AA5F3Q37293809-8E466753-6B3C-44CB-8752-BF5F05219F7EQ37337552-A2C9DF1B-D1E8-46DE-8F22-54E1C4A86331Q37512025-837D1A9A-305F-471F-82A0-E4F19936F3A6Q37734774-D2BCEE13-2EE3-47E3-B915-2C5297B4C3F6Q39208714-C8279140-81F5-42C9-AE5C-F4639781E677Q41325603-DC3ED855-C3B4-48B8-B6F2-AC4D152C4BBEQ42050715-428315C6-1657-4238-835E-7988E6211B4CQ42394229-DE1159C4-DF35-4F8D-AD4B-C2E6A6A6E503Q44293642-7959A746-5EAA-462E-9AAF-B9023E7B05B0Q44293645-7C41B866-3850-4B2F-9099-D75C8AC01ACDQ50919522-727B5E94-1ABA-4168-9813-BC77DFE8C026Q54620093-EADC980A-A7F6-42C6-8E17-04F278D8AD35
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Transthyretin amyloidosis: a tale of weak interactions.
@ast
Transthyretin amyloidosis: a tale of weak interactions.
@en
Transthyretin amyloidosis: a tale of weak interactions.
@nl
type
label
Transthyretin amyloidosis: a tale of weak interactions.
@ast
Transthyretin amyloidosis: a tale of weak interactions.
@en
Transthyretin amyloidosis: a tale of weak interactions.
@nl
prefLabel
Transthyretin amyloidosis: a tale of weak interactions.
@ast
Transthyretin amyloidosis: a tale of weak interactions.
@en
Transthyretin amyloidosis: a tale of weak interactions.
@nl
P2860
P1433
P1476
Transthyretin amyloidosis: a tale of weak interactions
@en
P2093
Saraiva MJ
P2860
P304
P356
10.1016/S0014-5793(01)02480-2
P407
P577
2001-06-01T00:00:00Z